Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G. Baumert, Roger Stupp, Monika E. Hegi et al.|The Lancet Oncology|2016Cited by 504
The Histone Variant H2A.Z Is a Master Regulator of the Epithelial-Mesenchymal TransitionRenae Domaschenz, David J. Tremethick, Sebastian Kurscheid et al.|Cell Reports|2017Cited by 61